KMT2A and leukemia: In summary, we have demonstrated that MLL leukemic cells under PI treatment can generally and intrinsically acquire an MLL dysfunction-mediated cell cycle deregulation resistant state (Fig. 7h), which reveals the phenotype switching mechanism may extend beyond MLL-rearranged B-ALL leukemias.